GRACE Targeted Therapies Patient Forum - English 2023

Leading oncologists come together in this 9th annual recorded live event to discuss targeted therapy options for patients with lung cancer. This series includes a Q&A with the audience, as well as presentations by leaders in the oncology field and patient advocates.

Thank you to our sponsors: #Takeda, #Janssen, #Lilly, #Genentech, #Mirati, #Exact Sciences, #BMS, and #GEHealthcare

For a list of all videos and transcripts, see https://cancergrace.org/targeted-therapies-lung-cancer-2023-live-patien…

GRACE Targeted Therapies Patient Forum - English 2022

In this 8th annual live patient forum, held on SATURDAY, JULY 16th, 2022, from 10 AM - 4 PM EST, leading thoracic oncologists from around the world, as well as lung cancer patients who are active within the patient advocacy community, discussed subjects relevant to all targets as well as breakout sessions on rare mutations.

This 6-hour live virtual webinar was an opportunity for lung cancer patients and caregivers to hear from experts and participate in live virtual question and answer sessions.  The forum offered panel discussions, live Q&A sessions, and breakout sessions focused on rare mutations such as EGFR, ALK, ROS, RET, and KRAS.  For more information visit the AGENDA and the FACULTY.

We thank our sponsors for this year's support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech

GRACE Targeted Therapies Patient Forum - English 2021

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty.

A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech